Acute Lymphoblastic Leukemia
Case Study

LatticePoint provided extensive client support while the internal market access team was being built

Background

• Product was acquired by mid-sized pharma
• Client had received pricing advice prior to LPC involvement
• The product was being sold via EAPs in several markets across Europe prior to receiving EMA approval

LatticePoint Engagement

• LatticePoint pricing strategy identified a commercial pricing increase relative to existing EAP priceWe developed the payer value proposition, global value dossiers and market entry strategy
• Develop launch sequencing to optimize list prices across the EU to minimize reference pricing impact to revenue
• Developed Health Economic models (cost-effectiveness, cost minimization, budget impact)
• Developed and submitted reimbursement dossiers, including:
  • Reinforce evidence arguments via systematic literature reviews (SLRs), meta-analyses and indirect comparisons
  • Developed Health Economic models (cost-effectiveness, cost minimization, budget impact) tailored for each country

Team operated as in-country reimbursement leaders for preparation and negotiation with national customers. Client achieved quality access and pricing in each country.